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Both 3-farnesyl salicylic acid and 3-geranyl salicylic acid were synthesized from 2,6-dibromophenol and showed low levels of antimicrobial activity against  
E. coli strains.   
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Of the major classes of antibiotics in use today, only the 
oxazolidinones and the lipopeptides were introduced after 2000 
[1,2].  Both of these antibiotic classes are used against Gram-
positive bacterial infections.  The recent report by Gupta and 
coworkers that 3-farnesyl-2-hydroxybenzoic acid (1), isolated from 
the leaves of Piper multiplinervium C. DC. (Piperaceae), showed 
anti-Helicobacter pylori activity (MIC 37.5 mg/mL) and 
antimicrobial activity at MICs in the µg/mL range against 
Staphylococcus aureus, Escherichia coli, and other Gram-negative 
bacteria prompted us to develop a synthesis of members of this 
class of compounds [3].  Interestingly, with its salicylic acid 
subunit, these compounds might also exhibit anti-inflammatory 
activity.  Related natural products include O-methylgrifolic acid (2) 
that was isolated from the lipophilic fraction of fresh P. dispanssus, 
and grifolic acid (3) that was isolated from an American Albatrellus 
species [4].  
 
                   
 
Figure 1: Natural products. 
 
Salicylic acids substituted in the 3-position have been prepared     
by Mannich condensations [5)] and by acylation [6].  Lau reported  
a useful synthesis of 3-alkyl salicylic acids in 2001 using a     
MOM-protected phenol [7].  We prepared the MOM ether of      
2,6-dibromophenol.  Alkylation of the anion generated from 
halogen-metal exchange with farnesyl bromide followed by another 
halogen-metal exchange and reaction with carbon dioxide produced 
the protected salicylic acid.  Unfortunately, the deprotection of the 
MOM group with aqueous acid gave a complex mixture, 
presumably due to reactions of the trisubstituted alkenes.  
 
To circumvent this difficulty, we generated the MEM ether of     
2,6-dibromophenol in 95% yield by the method of Corey, as shown 
in Scheme 1 [8].  Halogen-metal exchange, followed by reaction 
with farnesyl bromide [9], afforded the alkylated compound in 67% 
yield.  Halogen-metal exchange and carboxylation using gaseous 
carbon dioxide, followed by deprotection of the MEM ether with 
zinc bromide gave the natural product 1, albeit in only 10% yield 
over the last two steps.  Substitution of methyl chloroformate for the 
carbon dioxide gave the ester in 80% yield.  Deprotection of the 
MEM ether and base-mediated hydrolysis of the ester afforded 1 in 
50% yield over two steps.  This represents the first synthesis of 1.   
 
OH
BrBr
OH
HO2C
1. MEM-Cl
2. n-BuLi,
Farnesyl bromide
3. n-BuLi, ClCO2Me
4. ZnBr2
5. NaOH, MeOH 1   
 
Scheme 1: Synthesis of 1. 
 
The successful synthesis of 1 prompted us to prepare the geranyl 
analog 4.  Scheme 2 shows the synthesis of geranyl salicylic acid 
(4) from 2,6-dibromophenol and geranyl bromide [10] in 58% 
overall yield.   
 
 
 
Scheme 2: Synthesis of 4. 
 
Compounds 1 and 4, 3-allylsalicylic acid (5), prepared from 
salicylic acid [11], 3-benzylsalicylic acid (6), prepared from ortho-
benzylphenol using Reimer-Tiemann reaction followed by 
oxidation [12], and commercially available 3-phenylsalicylic acid 
(7), were tested against two strains of bacteria to determine their 
level of antimicrobial activity.  We used simple zone of inhibition 
assays in which compounds 1 and 4, 3-methylsalicylic acid and     
3-benzyl salicylic acid (~50 mg/mL), along with solvent (DMSO) 
alone, were applied to a 10 mm filter paper disc and positioned at 
the center of an agar plate that had been inoculated with wild      
type E. coli (strain K12).  Following incubation at 37oC for 24 h,   
the zone of inhibition (ZOI) was measured.  We observed that        
3-methylsalicylic acid, as well as solvent alone, failed to inhibit 
bacterial growth (ZOI= 0).   
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Figure 2:  Analogs 
 
The synthesis of salicylic acid 1 and analog 4 in four steps from 
commercially available 2,6-dibromophenol makes available a novel 
antibiotic for further biological evaluation.  Evaluation of 3-methyl 
salicylic acid and 1 and 4 showed that the alkene is important for 
biological activity.  Zone of inhibition assays yielded the following 
results. Strain MG1655, salicylic acid and DMSO solvent control: 5 
mm, compound 1: 5.5 mm, and compound 4: 7 mm; strain NR688, 
salicylic acid and DMSO: 5 mm, compound 1: 8 mm, and 
compound 4: 14 mm.  In contrast, the antibiotic tetracycline gave 
zones of inhibition of 10 mm (MG1655) and 12 mm (NR688).  
While compounds 1 and 4 showed low levels of antimicrobial 
activity against both E. coli strains, these results indicate that the 
antimicrobial activity reported by Rüegg et al. [3] cannot be 
explained solely by the presence of salicylic-acid derivatives.  
 
Experimental 
 
Antimicrobial activity assays: We tested the antimicrobial activity 
of the compound using a standard disc diffusion assay.  For this   
we inoculated 10 cm LB agar plates with overnight cultures of  
wild-type Escherichia coli K-12 along with a K-12 mutant (strain 
NR688) with impaired LPS biosynthesis showing heightened 
sensitivity to hydrophobic drugs [13]. Sterile filter paper disks       
(5 mm) were positioned at the center of the plates and impregnated 
with either 2 mg of each compound, or antibiotic control 
(tetracycline, 15 mg).  The diameter of the zone of inhibition of 
growth around each disk was recorded in mm after overnight 
incubation at 37°C. 
 
3-Farnesyl salicylic acid (1):  In an oven-dried flask under argon, 
2,6-dibromophenol (1.0 mmol) was dissolved in 10 mL dry 
dichloromethane.  To this were added diisopropylethylamine      
(5.0 mmol) and MEMCl (3.1 mmol).  The mixture was stirred at 
room temperature overnight, after which it was worked up with 
saturated NaHCO3 (5 mL), extracted with dichloromethane, and 
dried over MgSO4 and concentrated in vacuo.  Purification by silica 
gel chromatography (10% ethyl acetate in hexanes) yielded the 
protected phenol in 95% yield.    
1H NMR (300 MHz, CDCl3): δ 7.46 (d, J = 7.8 Hz, 2H), 6.82          
(t, J = 7.95 Hz, 1H), 5.23 (s, 2H), 4.07 (t, J = 4.65 Hz, 2H), 3.59    
(t, J = 4.65 Hz, 2H), 3.35 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ 151.7, 133.1, 126.8, 118.8, 98.6, 
71.9, 70.1, 59.3. 
HRMS (EI) m/z: exact mass calcd for C10H12Br2O3 337.9153, found 
337.9160. 
 
The MEM protected phenol (1.0 mmol) was dissolved in dry THF 
(10 mL) under argon at -78oC.  To this was carefully added a 
solution of n-BuLi (1.0 mmol) and the reaction stirred at -78oC for 
30 min.  The reaction mixture was treated with a solution of freshly 
prepared farnesyl bromide (1.0 mmol) in 5 mL THF.  The reaction 
was allowed to warm to rt where it was stirred overnight. The 
reaction was worked-up with aqueous NH4Cl, extracted with diethyl 
ether, and dried over MgSO4 and concentrated in vacuo.  
Purification via silica gel chromatography (5% ethyl acetate in 
hexanes) yielded the desired compound in 67% yield.   
1H NMR (300 MHz, CDCl3): δ 7.38 (d, J = 6.0 Hz, 1H), 7.12 (d, J = 
5.7 Hz, 1H), 6.92 (t, J = 5.85 Hz, 1H), 5.31-5.28 (m, 1H), 5.18 (s, 
2H), 5.14-5.07 (m, 2H), 4.01 (t, J = 3.5 Hz, 2H), 3.61 (t, J = 3.6 Hz, 
2H), 3.46 (d, J = 5.4 Hz, 2H), 3.40 (s, 3H), 2.13-1.95 (m, 8H), 1.69 
(s, 3H) 1.67 (s, 3H), 1.60 (s, 6H). 
13C NMR (75 MHz, CDCl3): δ 152.6, 137.6, 135.4, 133.6, 131.3, 
129.3, 128.7, 125.9, 124.5, 123.3, 118.4, 116.4, 98.8, 71.9, 69.7, 
59.3, 39.9, 39.5, 29.0, 27.0, 26.7, 26.0, 18.0, 16.4, 16.3. 
HRMS (EI) m/z: exact mass calcd for C25H37BrO3 464.1926, found 
464.1938. 
 
The farnesyl adduct (0.67 mmol) was dissolved in 10 mL dry THF 
at -78oC, where it was treated with n-BuLi (0.68 mmol) for 30 min.  
A solution of methyl chloroformate (1.0 mmol) in THF was added 
to the reaction mixture, which was then warmed to rt and allowed to 
stir overnight, after which the reaction was quenched with HCl. The 
reaction mixture was extracted with ethyl acetate, dried over 
MgSO4 and concentrated in vacuo. Purification via silica gel 
chromatography (15% ethyl acetate in hexanes) yielded the pure 
compound in 80 % yield.  
1H NMR (300 MHz, CDCl3): δ 7.64 (dd, J = 7.8 Hz, 1.8 Hz, 1H), 
7.34 (d, J = 7.5 Hz, 1H), 7.07 (t, J = 7.65 Hz, 1H), 5.32-5.27 (m, 
1H), 5.13 (s, 2H), 5.13-5.05 (m, 2H), 3.92 (t, J = 4.65 Hz, 2H), 3.87 
(s, 3H), 3.57 (t, J = 4.65 Hz, 2H), 3.46 (d, J = 7.2 Hz, 2H), 3.37    
(s, 3H), 2.12-1.96 (m, 8H), 1.67 (s, 3H), 1.66 (s, 3H), 1.58 (s, 6H). 
13C NMR (75 MHz, CDCl3): δ 167.0, 155.7, 137.3, 136.7, 135.5, 
134.1, 132.6, 129.4, 125.1, 124.6, 124.2, 122.2, 100.3, 71.9, 69.4, 
59.3, 52.3, 39.9, 32.2, 28.3, 26.9, 25.9, 23.6, 17.9, 16.4, 16.3. 
HRMS (EI) m/z: exact mass calcd for C27H41O5 445.2949, found 
445.2954. 
 
The MEM protecting group was removed using ZnBr2. The ZnBr2 
was freshly prepared by suspending oven-dried zinc powder (7.3 
mmol) in 10 mL dry THF. To this was added 1,2-dibromoethane 
(8.1 mmol) and the solution was heated to reflux overnight, during 
which time the color turned cloudy white. Methyl ester from the 
previous step (1 mmol) was added to the freshly prepared ZnBr2 
solution. The reaction mixture was stirred overnight at room 
temperature. The reaction was worked up with H2O, extracted with 
diethyl ether, dried over MgSO4 and concentrated in vacuo. 
Purification via silica gel chromatography (5% ethyl acetate in 
hexanes) yielded pure compound in 70% yield.  
1H NMR (300 MHz, CDCl3): δ 11.05 (s, OH), 7.69 (d, J = 8.1 Hz, 
1H), 7.32 (d, J = 7.5 Hz, 1H), 6.80 (t, J = 7.65 Hz, 1H), 5.36-5.31 
(m, 1H), 5.14-5.07 (m, 2H), 3.94 (s, 3H), 3.38 (d, J = 7.5 Hz, 2H), 
2.12-1.99 (m, 8H), 1.70 (s, 3H), 1.68 (s, 3H), 1.60 (s, 6H). 
13C NMR (75 MHz, CDCl3): 171.3, 159.9, 137.2, 135.4, 130.2, 
127.6, 125.2, 124.6, 124.3, 121.8, 118.8, 111.9, 52.4, 39.9, 32.2, 
27.8, 26.9, 26.7, 26.6, 26.0, 17.9, 16.3.  
HRMS (EI) m/z: exact mass calcd for C23H33O3 357.2424, found 
357.2430. 
 
To a solution of the phenolic compound (1 mmol) from the previous 
step in MeOH (5 mL) was added a solution of NaOH (4 mmol) in 
H2O (6 mL) and the resulting suspension was heated at 55
oC for 3 
h. After the reaction was complete, it was cooled to room 
temperature and washed with diethyl ether. The aqueous layer was 
acidified with 1N HCl and the suspension extracted with ethyl 
acetate, dried over MgSO4 and concentrated in vacuo to give the 
farnesyl salicylic acid (1) in 72% yield.  
1H NMR (300 MHz, CDCl3): δ 10.68 (s, OH), 7.79 (d, J = 7.8 Hz, 
1H), 7.39 (d, J = 7.2 Hz, 1H), 6.86 (t, J = 7.65Hz, 1H), 5.36-5.32 
(m, 1H), 5.15-5.07 (m, 2H), 3.39 (d, J = 7.5 Hz, 2H), 2.15-1.99 (m, 
8H), 1.72 (s, 3H), 1.68 (s, 3H), 1.60 (s, 6H). 
13C NMR (75 MHz, CDCl3): δ 175.4, 160.6, 137.3, 136.6, 135.3, 
130.5, 128.7, 125.2, 124.6, 124.3, 121.6, 119.2, 110.8, 40.2, 40.0, 
32.2, 27.9, 26.7, 25.9, 17.9, 16.4, 16.3.   
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HRMS (EI) m/z: exact mass calcd for C22H29O3 341.2122, found 
341.2129. 
 
3-Geranyl salicylic acid (4): The MEM-protected phenol (0.93 
mmol) in THF (10 mL) was treated with 2.5M n-BuLi (0.93 mmol) 
at -78oC for 30 min under argon.  The resultant mixture was treated 
with a solution of freshly prepared geranyl bromide (1.1 mmol) in 
THF (5 mL). The reaction mixture was allowed to warm to rt where 
it was stirred overnight.  The reaction was worked up with aqueous 
NH4Cl, extracted with diethyl ether, dried over MgSO4 and 
concentrated in vacuo. Purification via silica gel chromatography 
(5% ethyl acetate in hexanes) yielded the geranyl adduct in 83% 
yield.   
1H NMR (300 MHz, CDCl3): δ 7.49 (d, J = 6.0 Hz, 1H), 7.11 (d, J = 
6.0 Hz, 1 H), 6.93 (t, J = 6.0 Hz, 1H), 5.28 (t,  J = 6.0 Hz, 1H), 5.18 
(s, 2H), 5.10 (t,  J = 6.0 Hz, 1H), 4.02 (t, J = 6.0 Hz, 2H), 3.62 (t,    
J = 6.0 Hz, 2H), 3.46 (d,  J = 6.0 Hz, 1H), 3.40 (s, 3H), 2.10-2.05 
(m, 4H),1.68 (s, 6H), 1.60 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 152.6, 137.3, 133.6, 131.8, 131.3, 
129.3, 125.9, 124.4, 122.2, 117.6, 98.8, 71.9, 69.7, 59.3, 39.9, 29.0, 
26.8, 26.0, 18.0, 16.4. 
HRMS (EI) m/z: exact mass calcd for C20H29BrO3 396.1300, found 
396.1308. 
 
 
Geranyl adduct (0.77 mmol) was dissolved in 10 mL dry THF        
at -78oC, where it was treated with 2.5M n-BuLi (0.78 mmol) for  
30 min. Carbon dioxide gas was bubbled through the solution and 
warmed to room temp for 2 h.  The reaction was worked up with 
acetic acid and concentrated.  The crude product was used in the 
next step without further purification. 
 
Zinc bromide was prepared on the same scale as in the synthesis of 
1. The starting material was added to the zinc bromide solution in 
THF and stirred overnight.  The reaction was worked up with H2O, 
extracted with diethyl ether, dried over MgSO4 and concentrated    
in vacuo. Purification via silica gel chromatography (15% ethyl 
acetate in hexanes) yielded 4 as an off-white solid in 74% yield over 
2 steps.   
1H NMR (300 MHz, CDCl3): δ 10.72 (br, OH), 8.02 (d, J = 6.0 Hz, 
1H), 7.38 (d, J = 6.0 Hz), 7.03 (t, J = 6.0, 1H), 5.32 (t, J = 6.0 
Hz,1H), 5.10 (t, J = 6.0 Hz, 1H), 3.51 (d, J = 6.0 Hz, 1H), 2.03-1.96 
(m, 4H), 1.68 (s, 6H), 1.60 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 169.5, 153.1, 136.8, 136.0, 132.0, 
131.2, 124.2, 121.6, 119.7, 116.0, 47.8, 41.2, 39.8, 32.0, 23.1, 19.9. 
HRMS (EI) m/z: exact mass calcd for C17H22O3 274.1569, found 
274.1575. 
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